Send to

Choose Destination
Indian J Cancer. 2019 Jul-Sep;56(3):269-270. doi: 10.4103/ijc.IJC_139_18.

Diagnostic application of patent blue V in sentinel lymph node biopsy for breast cancer - Is it time for a change?

Author information

Department of Breast Surgery, Royal Wolverhampton Hospital, Wolverhampton, UK.
Department of Allergy and Immunology, Heart of England NHS Foundation Trust, Birmingham, UK.
Department of Allergy and Immunology, Heart of England NHS Foundation Trust; Birmingham Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham, UK.


Sentinel lymph node biopsy (SLNB) was introduced in the 1990s, as a minimally invasive procedure for staging the axilla with less morbidity to the traditional axillary lymph node dissection and is now standard management of the axilla in the early breast cancer. SLNB using the combined technique of blue dye and radioisotope is currently the recommended method for lymphatic mapping, and studies have shown high identification rates (IR) (>95%) and low false-negative rates (FNR) 5-10%. However, there are several reports raising awareness regarding patent blue V dye-induced peri-operative anaphylaxis. The main aim of this article is to highlight the emergence of patent blue dye as a new allergen and present evidence regarding the utility of alternative safer methods of evaluation of early breast cancer without compromising IR.


Allergy; blue dye; breast cancer; sentinel node

Free full text

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd
Loading ...
Support Center